News

Life Sciences

Epizyme Raises $75 Million in Follow-on Offering to Advance Epigenetic Cancer Therapies

Edward Kim | Equities.com |

Lead candidate, tazemetostat, in Phase 2 for non-Hodgkin lymphoma, solid tumors and mesothelioma (Image: Epizyme).


Paratek Gets FDA Approval for Moderate to Severe Acne Treatment

Edward Kim | Equities.com |

FDA is due to decide later this week on Paratek's lead compound for acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia (Image: Paratek)


Insmed Gets FDA Approval for First Mycobacterium Avium Complex (MAC) Lung Disease Therapy

Edward Kim | Equities.com |

First drug granted approval under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (Image: Bronchiectasis News Today)


KSQ Therapeutics Raises $80 Million Series C for Cancer Therapies

Edward Kim | Equities.com |

Proprietary CRISPRomics discovery engine has yielded 12 oncology programs in just 12 months (Image: KSQ Therapeutics)


Geron Announces Termination of Janssen Collaboration in Blood Cancer

Edward Kim | Equities.com |

Geron regains global rights to the imetelstat program and will focus on initiating Phase 3 studies (Image: Geron)


Lyra Therapeutics Raises $29.5 Million Series B for Chronic Rhinosinusitis

Edward Kim | Equities.com |

Financing led by Perceptive Advisors to advance ear, nose and throat disease therapies (Image: Lyra Therapeutics).


Verastem Gets its First FDA Approval for Blood Cancer Drug

Edward Kim | Equities.com |

For relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma (Image: Verastem)


Ra Medical Systems' $50 Million IPO Expected This Week

Edward Kim | Equities.com |

Excimer laser system to treat vascular and dermatological diseases (Image: Ra Medical Systems).


uBiome, Owner of Largest Human Microbiome Database, Raises $83 Million Series C Round

Edward Kim | Equities.com |

Moving into drug discovery and development. Also adds ex Novartis CEO Joseph Jimenez to board (Image: uBiome).


Molecular Templates Signs Cancer Therapy Development Deal with Takeda Worth up to $663 Million

Edward Kim | Equities.com |

Targeting CD38, a key biomarker in multiple myeloma and other cancers (Image: Molecular Templates).


Emerging Growth

Global Cannabis

Global Cannabis Applications Corp is engaged in the design, acquire data and develop applications for smartphones and tablets. The company offer Citizen Green platform, an end to end infrastructure to…

Events

Truth on Trial: Implications for Communicators – Part III

Truth on Trial” is just one of a series of forums put on by the Schar School of Policy & Government, whose panelists are among the most influential legal, communications,…

Learn more